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Royal jelly (RJ) has been used worldwide for many years as medical products, health foods and cosmet-
ics. Since RJ contains testosterone and has steroid hormone-type activities, we hypothesized that it may
have beneficial effects on osteoporosis. We used both an ovariectomized rat model and a tissue culture
model. Rats were divided into eight groups as follows: sham-operated (Sham), ovariectomized (OVX),
OVX given 0.5% (w/w) raw RJ, OVX given 2.0% (w/w) RJ, OVX given 0.5% (w/w) protease-treated RJ
(pRJ), OVX given 2.0% (w/w) pRJ, OVX given 17b-estradiol and OVX given its vehicle, respectively.
The Ovariectomy decreased tibial bone mineral density (BMD) by 24%. Administration of 17b-estradiol
to OVX rats recovered the tibial BMD decrease by 100%. Administration of 2.0% (w/w) RJ and
0.5–2.0% (w/w) pRJ to OVX rats recovered it by 85% or more. These results indicate that both RJ
and pRJ are almost as effective as 17b-estradiol in preventing the development of bone loss induced
by ovariectomy in rats. In tissue culture models, both RJ and pRJ increased calcium contents in femoral-
diaphyseal and femoral-metaphyseal tissue cultures obtained from normal male rats. However, in a
mouse marrow culture model, they neither inhibited the parathyroid hormone (PTH)-induced calcium
loss nor affected the formation of osteoclast-like cells induced by PTH in mouse marrow culture system.
Therefore, our results suggest that both RJ and pRJ may prevent osteoporosis by enhancing intestinal
calcium absorption, but not by directly antagonizing the action of PTH.
Keywords: bone mineral density – bone tissue culture – ovariectomized rats – post-menopausal
osteoporosis model – protease-treated RJ – royal jelly
Introduction
With the growing aged population, we urgently need to
develop new and effective treatments for chronic and protrac-
ted diseases, e.g. chronic pain, diabetes, arthritis, osteoporosis,
cancer as well as cardiovascular and brain ailments. Recently,
more and more unconventional therapies have been used for
treating these diseases (1–3).
The peak bone mass of women is less than that of men
because of the decrease in bone mass owing to menopause.
Therefore, women are vulnerable to bone loss known as post-
menopausal osteoporosis (4,5). The primary cause for this
symptom is an estrogen deficiency. An ovariectomized rat
model, which artificially produces estrogen deficiency, has
been used for the study of post-menopausal osteoporosis.
Both aged and mature rats have been employed as animal
models for experimentally induced osteoporosis. The mature
rat model has characteristics which are seen in early post-
menopausal bone loss (6). Using this model, several
compounds were screened and found to be effective for the
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(5,6), bisphosphonate (6,7), calcitonin (6,8), calcium products
(6,9) and anabolic steroids (10). Recently, efficacy of tradi-
tional Chinese (Kampo) medicines has been reevaluated by
clinicians (11). Kampo medicines have less side effects, and
therefore, seem to be more suitable for a long-term medication.
We reported their inhibitory effects on both the progression of
tibial bone loss and the alteration of periodontium induced by
ovariectomy in rats (12–15).
Royal jelly (RJ) is the principal food for the honeybee queen.
This is produced in the hypopharyngeal and mandibular glands
of worker honeybees and has been demonstrated to possess
several pharmacological activities, such as life-span-
elongating (16), antifatigue (17), antiallergic (18), antitumor
(19), antihypercholesterolemic (20), antihypertensive (21)
and anti-inflammatory effects (22). Indeed, RJ has been used
worldwide as commercial medical products, health foods and
cosmetics. The chemical composition of RJ was reported to
be proteins, sugars, lipids and vitamins (23). It contains many
bioactive substances such as 10-hydroxy-2-decenoic acid
(23), proteins mentioned above (17,18) and antibacterial pro-
tein (24). RJ contains testosterone and has activities similar
to other steroid hormones (20,25,26). Therefore, RJ may be
beneficial for osteoporosis. Although RJ has been traditionally
known to improve post-menopausal symptoms, to our know-
ledge, no one has studied whether or not it prevents the
decrease of bone mass, which is one of the deleterious symp-
toms for post-menopausal women.
Therefore, we undertook this study to evaluate the efficacy
of RJ and protease-treated RJ (pRJ) in preventing osteoporosis
using the mature rat model. We included pRJ because this is
known to enhance intestinal absorption of calcium (27). In
order to analyze the mechanism of action of these compounds,
their in vitro effects on the bone formation were also investig-
ated using a bone tissue culture model. We also examined
whether these compounds could antagonize the osteoporotic
actions of parathyroid hormone (PTH) in in vitro experiments.
Materials and Methods
In Vivo Experiments
RJ and Chemicals
Both dried powders of raw RJ and pRJ were supplied by
Yamada Apiculture Center, Inc., (Okayama Prefecture, Japan).
The constituents and contents of both RJ and pRJ used in this
study are shown in Table 1. 17b-Estradiol was purchased
from Sigma–Aldrich Co. (St Louis, MO, USA). All other
reagents were purchased from ABIOZ Co. Ltd (Osaka, Japan).
Ovariectomy and Administration of RJ
Forty-eight female Sprague–Dawley rats, aged 9 weeks, were
purchased from Seac Yoshitomi Ltd (Fukuoka Prefecture).
Twenty-seven days later [90-days-old; a mature rat model (6)
was used], six rats were given a sham operation (control rats;
first group) and 42 rats were bilaterally ovariectomized under
nembutal (pentobarbital sodium; 50 mg kg
 1 body weight:
Abbott Lab., IL, USA) anesthesia. They were also equally
divided into the second to the eighth groups. The second group
received orally MF powdered pellets (Oriental Yeast Co. Ltd,
Tokyo, Japan), which are designed for feeding rodents. Their
contents are 24% (w/w) proteins, 5.1% (w/w) lipids, 2.9% (w/
w) fibers and 6.1% (w/w) ashes. The third and fourth groups
orally received MF powdered pellets containing 0.5% (w/w)
(0.5 g RJ was mixed with 100 g MF powdered pellets; RJ-1)
and 2.0% (w/w) RJ (RJ-2). The fifth and sixth groups orally
received MF powdered pellets containing 0.5% (w/w) (pRJ-1)
and 2.0% (w/w) pRJ-2. Each ovariectomized rat in the seventh
group was injected subcutaneously with 17b-estradiol [in 20%
(v/v) polyethylene glycol 400] 5 days per week at a dose of
10 mgk g
 1 body weight (12,14). Rats in the eighth group were
injected with 20% (v/v) polyethylene glycol 400 (vehicle) in the
same manner as the seventh group.
To develop bone loss in ovariectomized rats, all animals
were maintained for 7 weeks under regulated 12 h/12 h light/
dark illumination cycles at constant temperature (24 ± 0.5 C)
and humidity (45–50%). Food and drinking water (tap water)
were supplied ad libitum.
The time for measuring daily food consumption and body
weight was the same during the entire period. After euthaniz-
ing the rat with cervical dislocation under chloroform anes-
thesia, the right leg was dissected from each animal. The
uterus of each rat was dissected and weighed (12,14).
Measurement of Bone Mineral Density
Afterremovingadherent soft tissues, longitudinalsectionofright
tibiae was prepared by manual grinding with whetstones (#600).
Table 1. Constituentsand contentsin royaljelly andprotease-treated royal
jelly
Constituents Contents Royal
jelly
Protease-treated
royal jelly
Water % (w/w) 1.5 4.0
Proteins % (w/w) 40.4 37.7
Carbohydrates % (w/w) 47.1 45.3
Lipids % (w/w) 8.0 4.4
Ashes % (w/w) 3.0 8.6
Minerals
Sodium mg per 100 g 38.7 3000
Phosphorus mg per 100 g 661 619
Calcium mg per 100 g 18.7 30.5
Magnesium mg per 100 g 91.7 83.9
Zinc mg per 100 g 6.3 7.6
Iron mg per 100 g 3.0 3.1
Free amino acids mg per 100 g 1569 4780
340 Royal jelly in osteoporosis preventionAll longitudinal specimens were dehydrated by a step-
wise application of 70 and 99.9% (v/v) ethanol solutions.
These samples were used for both bone mineral density (BMD)
measurements and scanning electron microscope (SEM)
observations.
The BMD was quantitatively determined by the computed
X-ray densitometry (CXD) method (Bonalyzer; Teijin Com-
pany, Tokyo, Japan) (12,14). The radiographs of the longitud-
inal sections of tibiae were taken along with an aluminum
step-wedge using an X-ray apparatus (Model CSMW-2 Spe-
cific; Softex Co., Tokyo, Japan) set at 5 mA, 40 cm, 30 s,
50 V and 55 kVp. The densitometric pattern of the proximal
tibia on an X-ray picture was read by a personal computer
(PC-9801; NEC, Tokyo, Japan) using a software program for
rat bone density (Version 2.10A-M; Teijin Company). SGS
(mm Al) and SGS/D were used as the indices of bone mineral
content (BMC) and BMD, respectively. Here, the value for
SGS was obtained by integrating the pattern area, which was
obtained opticodensitometrically and was converted into a
number of steps in an aluminum step-wedge. D represents
the bone width. The value for SGS/D was calculated for the
areas that cover the epiphysis and a part of metaphysis in the
proximal tibia. The determination of the area and the precision
of the measurements were described by Hidaka et al. (12).
Electron Microscopic Observations
Longitudinal sections of tibiae were shadowed with carbon
before examination in a SEM (JSM-6330F; Nihon Denshi,
Tokyo, Japan) at 10 kV.
In Vitro Experiments
Chemicals
Dulbecco’s modified Eagle’s medium (DMEM) (high glucose,
4.5 g dl
 1) and a penicillin–streptomycin solution (penicillin
5000 U mg
 1; streptomycin 5000 mgm l
 1) were purchased
from Gibco Laboratories (Grand Island, NY, USA). PTH [syn-
thetic human PTH (1–34)] was purchased from Sigma–Aldrich
Co. All other reagents were purchased from Wako Pure
Chemical Industries (Osaka, Japan).
Male Rats or Mice for Bone Tissue Cultures
Male Wistar rats weighing 90–100 g (4 weeks old) or male
mice (ddY strain; 6 weeks old) were obtained from Japan
SLC (Hamamatsu, Japan). The animals were fed with a com-
mercial laboratory chow containing 1.1% calcium and 1.1%
phosphorus at a room temperature of 25 C, with free access
to distilled water.
Bone Culture Experiments
Under ether anesthesia with cervical dislocation, the femurs of
male rats were removed aseptically after bleeding and were
then soaked inice-cold 0.25 M sucrose solution. The soft tissue
and marrow were cleaned-off from the femur, and the
diaphysis and metaphysis (not containing epiphyseal tissue)
were separated by a morphological tool. The femoral-
diaphyseal and femoral-metaphyseal tissues were cut into
small pieces (the size of about 2 · 2 mm) by a pair of scissors.
Diaphyseal or metaphyseal fragments (pieces of 3 or 4) were
cultured for 48 h in a 35 mm dish in 2.0 ml of medium consist-
ing of Minimum essential medium (MEM) (high glucose,
4.5 g dl
 1) supplemented with antibiotics (penicillin 100 units
and streptomycin 100 mgm l
 1) (28). In order to determine the
effects of RJ and pRJ on bone calcium content, bone tissues
were cultured in a medium containing either 10–100 mgm l
 1
RJ or 50–100 mgm l
 1 pRJ in the presence or absence of
10
 7 M PTH. Both RJ and pRJ were soluble in the culture
medium.
Cultures were maintained at 37 C in a water-saturated atmo-
sphere containing 5% CO2 and 95% air. After culture, the dia-
physeal or metaphyseal tissues were removed, washed with
ice-cold 0.25 M sucrose solution and dried for 16 h at 110 C.
The calcium content was determined by atomic absorption
spectrophotometry (28,29). The concentration of calcium in
the medium containing RJ or pRJ was in the range of
0.05–1.0 mgm l
 1 of medium. The calcium content in the
bone tissue was expressed as mg g of dry bone. All experi-
mental data are mean ± SE for six animals.
Marrow Culture Experiments
Bone marrow cells isolated from male mice were used. Briefly,
both bone ends of the femur were cut-off, and the marrow cav-
ity was flushed with 1 ml of a-MEM. The marrow cells
obtained from six animals were washed with a-MEM and cul-
tured in the same medium containing 10% heat-inactivated
fetal bovine serum at 1.0 · 10
7 cells per ml in 24-well plates
(0.5 ml per well) in a water-saturated atmosphere containing
5% CO2 and 95% air at 37 C. The cells were cultured for
3 days, then 0.2 ml of the old medium was replaced with fresh
medium and the cultures maintained for an additional 4 days
(30,31). RJ or pRJ was added to the culture medium containing
either the vehicle or PTH (10
 7 M) (or the vehicle) at the
beginning of the culture and at the time of medium change.
Enzyme Histochemistry
After being cultured for 7 days, cells which adhered to the
24-well plates were stained for tartrate-resistant acid phos-
phatase (TRACP), a marker enzyme of osteoclasts (32,33).
Briefly, cells were washed with the Hank’s balanced salt solu-
tion and fixed with 10% neutralized formalin-phosphate
(pH 7.2) for 10 min. After the culture dishes were dried,
TRACP staining was applied according to the method of
Burstone (32). The fixed cells were incubated for 12 min at
room temperature (25 C) in an acetate buffer (pH 5.0) contain-
ing 10 mM sodium tartrate and naphthol AS-MX phosphate
(Sigma) as a substrate, and red violet LB salt (Sigma) as a stain
for the reaction product. TRACP-positive multinucleated cells
(MNCs) containing three or more nuclei were counted as
osteoclast-like cells.
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The ovariectomy analyses were performed at the Fukuoka
Dental College. The tissue culture experiments were carried
out at the University of Shizuoka. The study was approved by
the Institutional Use and Care of Animal Committee of the
respective university. All procedures were in accordance with
theGuidelinesonAnimalExperimentsineitherFukuokaDental
College or University of Shizuoka of Japan, and performed fol-
lowing the Government Law Concerning the Protection and
Control of Animals (No. 221) and Japanese Government Noti-
fication on Feeding and Safekeeping of Animals (No. 6).
Satistics
Data were obtained from three measurements and expressed as
means ± standard deviations. Data of tissue cultures were
expressed as means ± standard errors. Statistical comparisons
were made by ANOVA with Fisher’s Protected Least
Significant Differencetest using a statisticalsoftware program.
The difference was considered significant when P < 0.05.
Results
Food Consumption and Body Weight
As shown in Fig. 1, the mean daily food consumption of the
Sham, OVX þ Est and OVX þ pRJ-2 rats increased and
reached a plateau at Week 2 after surgery, while that of food
consumption of the remaining five groups increased until
Week 3 after surgery and then leveled off (data of
OVX þ RJ-1,þ pRJ-1 and þ Peg rats were not shown).
Since food consumption in Week 1 was particularly smaller
than that in the following weeks, two values (Week 1 and
Weeks 2–7) were examined separately. As shown in Fig. 2,
the mean daily food consumption of the OVX rats in Week 1
was comparable with all other groups. However, that of OVX
rats in Weeks 2–7 was higher than that of Sham rats by 21%.
The daily food consumption for OVX þ RJ-2 rats in Weeks
2–7 was 20.7 g (Fig. 2). The food for this group contains 2.0 g
RJ per 100 g [2.0% (w/w)]. Therefore, the daily consumption
of RJ was 0.41 g. Since the body weight of a rat varied from
280 to 378 g (Figs 3 and 4A), the daily dose of RJ was between
1.08 and 1.46 g kg
 1 (an average 1.27 g kg
 1) body weight.
The daily dose taken by RJ-1 rats was about one-fourth
(0.32 g kg
 1) of that in RJ-2 rats. Similarly, the daily food con-
sumption for OVX þ pRJ-2 rats in Weeks 2–7 was 19.4 g
(Fig. 2). The food for this group contains 2.0 g pRJ per 100 g
[2.0% (w/w)]. The daily consumption of pRJ was 0.39 g. Since
the body weight of a rat varied from 280 to 370 g (Figs 3 and
4A), the daily dose of pRJ was between 1.05 and 1.39 g kg
 1
(an average 1.22 g kg
 1) body weight. The daily dose taken
by pRJ-1 rats was about one-fourth (0.31 g kg
 1) of that in
pRJ-2.
The increase of body weight in ovariectomized (OVX) rats
was significantly higher than that in sham control (Sham) rats
(Fig. 3). After Week 7, the mean body weight ± SD in Sham
and OVX rats were 315 ± 11 (n ¼ 6) and 375 ± 13 (n ¼ 6),
respectively (Fig. 4A). The increases in the body weight
of OVX þ RJ-1, þ RJ-2, þ pRJ-1, þ pRJ-2 and þ Peg
rats were similar to that in OVX rats (data of
OVX þ RJ-1, þ pRJ-1 and þ Peg were not shown). With the
administration of the 17b-estradiol to OVX rats (OVX þ Est),
the increase was reduced to almost the same level as that for
Sham rats (Figs 3 and 4A).
Uterine Weight
As shown on the right side of Fig. 4A, the uterine weight of
OVX rats decreased significantly from that of the Shams
(P < 0.01). The weight in the OVX þ RJ-1, þ RJ-2,
þ pRJ-1 or þ pRJ-2 group was almost the same as that in
the OVX group. The weight of the group injected with
17b-estradiol was similar to that of the Sham rats. The weight
of the group injected with the vehicle was almost as high as
that of the OVX rats.
Bone Mineral Density
As shown in Fig. 4B, the tibial BMD of OVX rats
(0.50 ± 0.01) was 24% lower than that of Sham
(0.66 ± 0.01). The administration of the 2.0% (w/w) RJ and
0.5–2.0% (w/w) pRJ to the rats significantly recovered the
BMD. However, the administration of 0.5% (w/w) RJ to
OVX rats did not recover the BMD. The recoveries with
2.0% (w/w) RJ, 0.5% (w/w) pRJ and 2.0% (w/w) pRJ were
85, 87 and 93% of that with 17b-estradiol. The injection of
17b-estradiol to OVX rats restored BMD almost completely
to the level of the Sham rats. The vehicle had no effect.
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Figure 1. Changes in the food consumption of rats. Rats were sham-operated
(open circles), ovariectomized (OVX) (closed circles); ovariectomized and
administered with 2.0% (w/w) RJ (open triangles), 2.0% (w/w) protease-
treated RJ (closed triangles) and 17b-estradiol (open squares). Data of
OVX administered 0.5% (w/w) RJ, 0.5% (w/w) protease-treated RJ and
20% (v/v) polyethylene glycol 400 were not shown. Each point represents
the mean ± SD (n ¼ 6). *P < 0.05, significant difference from the
ovariectomized group at the respective time.
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The representative scanning electron micrograph of the prox-
imal tibiae taken at 7 weeks after the ovariectomy is shown
in Fig. 5B. Compared to that of Sham rats (Fig. 5A), the con-
nectivity of cancellous bone in the epiphysis and that of tra-
becular bone in the metaphysis exhibited greater loss. The
administration of 17b-estradiol restored the connectivity in
the metaphysis to those of the Sham rats, whereas the vehicle
had no effect (Fig. 5C and D). The administration of 2.0%
(w/w) RJ and 0.5% (w/w) pRJ slightly restored the connectiv-
ity (Fig. 6B and C), but 0.5% (w/w) RJ did not (Fig. 6A).
The administration of 2.0% (w/w) pRJ (Fig. 6D) restored the
connectivity in the metaphysis to the level of those of
17b-estradiol rats.
Calcium Contents in Bone Tissues
As shown in Fig. 7, the calcium content in the diaphyseal or
metaphyseal tissues significantly increased when the bone tis-
sues were cultured in the presence of 50–100 mgm l
 1 RJ or
50–100 mgm l
 1 pRJ. However, as shown in Fig. 8, the pres-
ence of PTH (10
 7 M) induced a significant decrease in
calcium content in the diaphyseal or metaphyseal tissues.
This decrease was not significantly prevented in the presence
of RJ (50–100 mgm l
 1) or pRJ (50–100 mgm l
 1).
Figure 2. Mean daily food consumption in sham-operated and ovariectomized rats treated with various compounds for 7 weeks. Rats were divided into eight
groups, sham-operated (Sham), ovariectomized (OVX), OVX given 0.5% (w/w) RJ (OVX þ RJ-1), OVX given 2.0% (w/w) RJ (OVX þ RJ-2), OVX given
0.5% (w/w) pRJ (OVX þ pRJ-1), OVX given 2.0% (w/w) pRJ (OVX þ pRJ-2), OVX given 17b-estradiol (OVX þ Est) and OVX given polyethylene glycol
400 (OVX þ Peg), each having six rats. *Significant difference (P < 0.05) when compared with the Sham rats.
Figure 3. Changes in the body weight of rats. Rats were sham-operated (open
circles), ovariectomized (OVX) (closed circles); ovariectomized and admin-
istered with 2.0% (w/w) RJ (open triangles), 2.0% (w/w) pRJ (closed triangles)
and 17b-estradiol (open squares). Data of OVX administered 0.5% (w/w) RJ,
0.5% (w/w) pRJ and 20% (v/v) polyethylene glycol 400 were not shown.
Each point represents the mean ± SD (n ¼ 6). *P < 0.05 and **P < 0.01,
significant difference from the ovariectomized group at the respective time.
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As shown in Fig. 9, the presence of PTH caused a significant
increase in osteoclast-like cell formation in mouse marrow
culture system in vitro. This increase was not significantly sup-
pressed by either RJ (1–100 mgm l
 1) or pRJ (1–100 mgm l
 1).
Discussion
It has been reported that ovariectomy (OVX) increased
food intake and body weight and these changes could be
inhibited or reversed by treatment with estradiol (12,14,34).
In fact, the mean daily food consumption of OVX rats in
Figure 4. (A) Either body weight (white bar) and uterine weight (black bar) or (B) tibial BMD of sham-operated rats and those of ovariectomized rats treated with
various compounds for 7 weeks. Abbreviations were the same as those shown in Fig. 2. *Significant difference (P < 0.05) when compared with Sham rats.
**Significant difference (P < 0.05) when compared with OVX rats.
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Figure 5. Representative scanning electron micrographs of the longitudinal sections of the proximal tibia sampled at Week 7 after ovariectomy from (A)
sham-operated, (B) ovariectomized (OVX), (C) OVX given 17b-estradiol and (D) OVX given the vehicle.
344 Royal jelly in osteoporosis prevention2–7 weeks was higher than that of Sham rats by 21% (Fig. 2).
The administration of 17b-estradiol preserved the level of
normal food consumption (Figs 1 and 2). Since neither RJ
nor pRJ caused a decrease in food consumption in ovariec-
tomized rats (during Weeks 2–7), their effect seems to be
different from that of estrogen. However, it is noticed that
2% (w/w) pRJ seems to have a greater effect than its lower
concentration [0.5% (w/w)] or both RJ’s concentrations.
Both values of the food intake and the weight gain of
OVX þ pRJ-2 rats were below those for OVX rats (Figs 1
and 3). Their food consumption reached a plateau at 2 weeks
similar to that of the Sham rats.
OVX also caused an increase in body weight (Figs 2 and
4A), which had been postulated not only to be associated
with regulatory effect of estrogen on the adipose tissue (35)
but also to provide a partial protection against the development
of osteoporosis (36). The increase in food consumption in
ovariectomized rats (21% increase as described above) may
in part contribute to the increase in body weight (12,14). How-
ever, OVX rats gained more weight than Sham control rats in
the pair-fed condition (37,38). Therefore, we conclude that
OVX rats seem to make more efficient use of their food (39).
A marked atrophy of the uterus has been used as evidence of
the success of ovariectomy, because estrogen directly influ-
ences uterine weight (12). Indeed, ovariectomy also resulted
in a dramatic decrease in uterine weight (Fig. 4B). Since both
RJ and pRJ did not increase uterine weight, it is suggested
that these agents do not influence the actions of estrogen or
its receptor (40).
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Figure 6. Representative scanning electron micrographs of the longitudinal sections of the proximal tibia sampled at Week 7 after ovariectomy of rats. (A)
Ovariectomized (OVX) given 0.5% (w/w) RJ, (B) OVX given 2.0% (w/w) RJ, (C) OVX given 0.5% (w/w) pRJ and (D) OVX given 2.0% (w/w) pRJ.
Figure 7. RJ and pRJ on the calcium contents in the femoral-diaphyseal and
femoral-metaphyseal tissues obtained from normal rats in vitro. Bone tissues
were cultured for 48 h in a medium containing vehicle, RJ or pRJ. Each value
is the mean ± SE for six rats. RJ, royal jelly; pRJ, protease-treated royal jelly.
*Significant difference (P < 0.05) when compared with the control.
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believed to be a prominent inhibitory effect against bone
loss. The administration of 2.0% (w/w) RJ, 0.5% (w/w) pRJ
and 2.0% (w/w) pRJ to the OVX rats recovered BMD by 14,
16 and 24%, after 7 weeks, while that of 17b-estradiol
recovered BMD by 34%. The efficacy of the inhibition of
bone loss by 2.0% (w/w) RJ, 0.5% (w/w) pRJ and 2.0% (w/
w) pRJ was 41, 47 and 71% of that of 17b-estradiol. The
efficacy of pRJ on the tibial BMD was greater than that of RJ.
Ovariectomy resulted in a decrease in the connectivity of
cancellous bones in the epiphysis and that of the trabecular
bones in the metaphysis (Fig. 5A and B). Our data show that
pRJ was more effective than RJ in inhibiting the elution of
bone calcium, because the connectivity in OVX rats was
restored by the administration of 2.0% (w/w) pRJ. The
appearance was comparable with that of the Sham rats
(Figs 5A and 6D).
After the protease treatment of RJ, the contents of sodium,
calcium and free amino acids increased by 7.8, 1.6 and 3.0
times (Table 1). Their increased content of sodium was derived
from the addition of NaOH, which was used to adjust pH
during the protease treatment. The reason for the increase of
calcium content is not known. However, the effects of these
increases may be small because food itself contains large
amounts of sodium and calcium, and because the percentages
of RJ and pRJ in the food are very small.
Nakasa et al. (27) reported that pRJ significantly promoted
calcium absorption in the intestine as compared to that of
raw RJ. Therefore, it is conceivable that the greater effect of
pRJ may be caused by the enhanced digestibility (or utility)
and by its promotion of calcium absorption in the intestine.
The protease treatment of RJ eliminates the protein fractions
above 10 000 molecular weight from RJ, leaving the peptides
of 500–3000 molecular weight (MW) (27). Phosphoserine or
Figure 8. RJ and pRJ on the PTH-induced decrease in calcium content in the femoral-diaphyseal or femoral-metaphyseal tissues of the rat obtained from normal
rats in vitro. Bone tissues were cultured for 48 h in a medium containing vehicle, RJ or pRJ in the presence or absence of PTH (10
 7 M). Each value is the mean ±
SE for six rats. PTH, parathyroid hormone; RJ, royal jelly; pRJ, protease-treated royal jelly. *Significant difference (P < 0.05) when compared with the control.
Figure 9. RJ and pRJ on the PTH-induced osteoclast-like cell formation in mouse marrow cultures in vitro. Mouse marrow cells were cultured for 7 days in a
medium containing vehicle, RJ or pRJ in the presence or absence of PTH (10
 7 M). Each value is the mean ± SE for four wells. PTH, parathyroid hormone;
RJ, royal jelly; pRJ, protease-treated royal jelly. *Significant difference (P < 0.01) when compared with the control.
346 Royal jelly in osteoporosis preventionacidic amino acids contained in peptides in pRJ could select-
ively bind calcium and facilitate calcium transport across the
intestinal membranes.
As opposed to the in vivo models, both RJ and pRJ were sim-
ilarly effective in increasing the calcium contents in the rat
femoral-diaphyseal and femoral-metaphyseal tissue culture
models (Fig. 7). However, they did not inhibit the
PTH-induced calcium loss in the femoral tissues and
PTH-induced formation of osteoclast-like cells in mouse mar-
row culture system in vitro (Figs 8 and 9). These observations
demonstrated that both RJ and pRJ have a stimulatory effect on
bone formation, but that they do not have an inhibitory effect
on bone resorption.
Combining these in vivo and in vitro results, we speculate
that the mechanism of action of RJ or pRJ is to stimulate cal-
cium absorption of bone. The greater efficacy of pRJ in the
animal model may be derived from the enhancement of intest-
inal calcium absorption by pRJ. However, we cannot exclude
the possibility that other factors, such as calcium-regulatory
hormones or cytokines, are also involved.
Recently, estrogen replacement therapy (ERT) has raised
serious concerns about its safety because of tumor-inducing
side effects (41). Our initial study shows that the RJ products
may be used as alternative agents for the treatment of osteopor-
osis without such side effects, may be different from that for
Kampo medicines or isoflavones (12,14). Since RJ contains a
male hormone testosterone (25), this agent may also be effect-
ive in men’s osteoporosis that could be induced by a decrease
of androgen (42).
In summary, both RJ and pRJ inhibited the progression of
bone loss induced by ovariectomy in rats to a similar degree
to that of 17b-estradiol. The results of in vitro tissue culture
suggested that both nutrients increased calcium content of the
femoral tissues. Our data indicated that pRJ seems to be
more efficacious. We believe that pRJ may be useful in
humans for the prevention of not only post-menopausal osteo-
porosis but also osteoporosis in general.
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